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ABSTRACT
Objective: The present paper describes a simple, accurate, and precise reversed-phase high-performance liquid chromatography (HPLC) method for 
rapid and simultaneous quantification of dolutegravir (DTG) and rilpivirine (RPV) in bulk and pharmaceutical dosage form and rat plasma.
Methods: The chromatographic separation was achieved on Phenomenex C18 (150x4.6mm, 5µm). Mobile phase contained a mixture of 0.1% Ortho 
phosphoric acid and acetonitrile in the rato of 60:40 v/v, flow rate 1.0ml/min and ultraviolet detection at 262nm. 
Results: The retention time of DTG and RPV was 4.35 min and 7.73 min, respectively. The proposed method shows a good linearity in the concentration 
range of 10–150 µg/ml for DTG and 5–75 µg/ml for RPV under optimized conditions. Precision and recovery study results are in between 98 and 
102%. In the entire robustness conditions, percentage relative standard deviation is <2.0%. Degradation has minimum effect in stress condition and 
solutions are stable up to 24 h. DTG and RPV drugs are release 98% at 2 h in rat body.
Conclusion: This method is validated for different analytical performance parameters like linearity. Precision, accuracy, limit of detection, limit of 
quantification, robustness, and pharmacokinetic study were determined according to the International Conference of Harmonization (ICH) Q2B 
guidelines. All the parameters of validation were found in the acceptance range of ICH guidelines. The same method is also applied for plasma samples 
study in bioanalytical work.
Keywords: Reversed-phase high-performance liquid chromatography, Dolutegravir, Rilpivirine and rat plasma.
INTRODUCTION
Dolutegravir (DTG) marketed name as Tivicay is an antiretroviral 
medication [1] used together with other medication to treat 
human immunodeficiency virus (HIV)-acquired immune deficiency 
syndrome [2]. It may also be used, as part of post-exposure 
prophylaxis [3] to prevent HIV infection following potential 
exposure [4]. It is taken by mouth. DTG is an HIV integrase strand 
transfer inhibitor [5] which blocks the functioning of HIC integrase [6] 
which is needed for viral replication.
RLP is a pharmaceutical drug [7-9] developed by Tibotec for the 
treatment of HIV infection [10]. It is the second-generation non-
nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, 
longer half-life [11], and reduced side effect profile [12] compared with 
older NNRTIs such as efavirenz [13,14].
The literature survey revealed that there are only two methods 
reported high-performance liquid chromatography (HPLC) [15,16] and 
in ultraviolet (UV) spectrophotometric methods [17] two reports for 
only DTG [18,19]. There are no common methods for both quantitative 
analysis and bioanalytical [20] method.
The objective of the present work was the development and validation 
of a method for the estimation of DTG and rilpivirine (RPV).
METHODS
Instrumentation
The analysis was performed on Water Alliance-e2695 chromatographic 
system equipped with a quaternary pump and photodiode array 
detector-2996. Chromatographic software Empower-2.0 was used for 
data collection.
Chemicals and reagents
Acetonitrile (HPLC grade), orthophosphoric acid (HPLC grade), and 
water (HPLC grade) were purchased from Merck (India) Ltd., Worli, 
Mumbai, India. DTG and RPV reference standards were produced from 
Glenmark Pharmaceuticals Limited, Mahape, Navi Mumbai, India.
Chromatographic conditions
Chromatographic analysis was done using isocratic elution, mobile 
phase in the ratio of acetonitrile: buffer (0.1% o-phthaldialdehyde) 
(60:40 v/v) was filtered through 0.45 µ membrane filter paper. The flow 
rate of the mobile phase was monitored at 1.0 ml/min and eluents were 
detected at 262 nm. By injecting the volume 10µl with a run time 10min.
Selection of wavelength
Using photodiode spectrophotometer, the absorption spectra of the 
solution of two drugs are scanned in the UV region 200–400 nm spectra 
are shown in Fig. 1. The spectra of the DTG and RPV show at different 
λmax, namely 258.3 nm and 265.4 nm, respectively. By average, the two 
wavelengths at 262 nm were selected as detection wavelength for HPLC 
chromatographic method.
Preparation of standard solution
100 mg of DTG and 50 mg of RPV working standards were weighed 
accurately and transferred into a 100 ml volumetric flask. Added 70 ml 
of mobile phase sonicated for 20 min to dissolve the components 
makeup to the mark with diluent and mixed. After that, 5 ml of above 
solution diluted to 50 ml with mobile phase.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Preparation of sample solution
Weighed 20 tablets and take the one tablet equivalent weight. Crush the 
20 tablets into powder form take 10 tablets equivalent weight of sample 
into a 100 ml volumetric flask added 70 ml of diluent sonicated for 30 min 
after that makeup to the volume with diluent. Further diluted 5–50 ml 
with mobile phase and filtered through 0.45 µ nylon syringe filter.
Preparation of rat plasma sample preparation
The liquid-liquid extraction method was used to isolate DTG and RPV in rat 
plasma. For this, 100 µl of plasma sample (respective concentration) were 
added into labeled polypropylene tubes and vortexed briefly after that 2.5 ml 
of acetonitrile was added and vortexed for approximately 10 min followed 
by centrifuging at 4000 rpm at 20°C. Supernatant from each sample was 
transferred to labeled through tube and evaporated at 40°C until dryness. 
These samples were reconstituted with 500 µl of acetonitrile and vortexed 
briefly and then transferred the sample into autosampler vials for injection.
Validation
System suitability
As per the test method, the standard solutions were prepared and 
injected into HPLC system from which the evaluated system suitability 
parameters are found to be within the limit.
Specificity
The specificity defined as the ability of the method to measure the analyte 
accurately and specifically in the presence of components present in the 
sample matrix was determined by analysis of chromatograms of drug-
free and drug-added placebo formulation.
Linearity
The ability of the method to produce results those are directly or 
indirectly proportional to the concentration of the analyte in samples 
within a given range.
Precision
The degree of closeness of the agreement among individual test results 
when the method is applied to multiple samplings of a homogeneous 
sample. It is a measure of either the degree of reproducibility 
(agreement under different conditions) or repeatability (agreement 
under the same conditions) of the method.
Accuracy
The closeness of results was obtained by a method to the true value. It 
is a measure of the exactness of the method.
Limit of detection and quantification
The detection of limit and quantification limit for each analyte 
were determined based on a signal-to-noise concept, as the lowest 
concentration at which signal-to-noise ratio between 3 or 2:1 and 
10:1, respectively, with defined precision and accuracy under the given 
experimental conditions.
Stability
Standard and sample solutions were subjected to 24 h stability at RT 
and 2–8°C. The stability of these solutions was studied and observed for 
changes in the area and retention time of the peaks which were then 
compared with the pattern of the chromatogram of the freshly prepared 
solution.
Robustness
Robustness of the method was studied by slightly changes in 
experimental conditions such as flow rate and organic composition. This 
was performed by same analyst with same instrument.
Ruggedness
Ruggedness of the method was studied using different source of analysts, 




In this method, system suitability, linearity, precision, accuracy, robustness, 
limit of detection (LOD), limit of quantification (LOQ), forced degradation, 
and stability are validated for the selected DTG and RPV drugs.
System suitability
100µg/ml of DTG and 50µg/ml of RPV was prepared and injected into 
the HPLC system. Resolution of the DTG was 13.21 from the RPV. The 
number of theoretical plate counts for DTG and RPV was 6261 and 
11,234 respectively. Tailing factor for DTG and RPV was 1.06 and 1.14, 
respectively (Fig 2).
Linearity
Linearity of the method was evaluated by preparing a standard 
solution containing 100 µg/ml of DTG and 50 µg/ml of RPV (100% 
of targeted level of the assay concentration). Sequential dilutions 
were performed to give solutions at 10, 25, 50, 100, and 150% of the 
target concentrations. These were injected and peak areas used to plot 
calibration curves against the concentration. The correlation coefficient 
values of these three analytes were 0.999. The results are shown in 
Table 1 and Figs. 3 and 4.
Limit of detection and quantification
Limit of detection and quantification minimum concentration level 
at which the analyte can be reliably detected, quantified using the 
standard formulas (3.3 times σ/s for LOD and LOQ, respectively). 
LOD values for DTG and RPV were 0.01 µg/ml and 0.005 µg/ml 
Fig. 1: Photodiode array spectrum for dolutegravir and rilpivirine
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their s/n values are 3 and 4, respectively. LOQ values for DTG and 
RPV were 0.1 µg/ml and 0.05 µg/ml their s/n values are 23 and 26, 
respectively.
Precision
Method precision was investigated by the analysis of six separately 
prepared samples of the same batch. From this, six separate sample 
solutions were injected to obtain their areas. The calculate mean and 
percentage relative standard deviation (RSD) values. The present 
method was found to be precise as percentage RSD of <2%, and also, 
the percentage assay values were close to being 100%. The results are 
given in Table 2.
Accuracy
Accuracy was determined by recovery studies which were carried 
out in three different concentrations levels (50, 100, and 150%). 
APIs with concentration of 50, 100, and 150 µg/ml of DTG; 25, 50, 
and 75 µg/ml of RPV were prepared. As per the test method, the test 
solution was injected three preparations each spike level and the 
assay was performed. The percentage recovery values were found 
to be in the range of 100.22–100.45% for DTG and 100.37–100.58% 
for RPV. RSD values were found to be <2%. The results are given in 
Table 3.
Ruggedness
Ruggedness of the method was studied and showed that 
chromatographic patterns did not significantly change when different 
HPLC system, analyst, and column. The value of percentage of RSD was 
<2% and exhibits the ruggedness of the developed method.
Robustness
Robustness of the method found to be percentage RSD should be <2%. 
Slightly variations were done in the optimized method parameters such 
Fig. 2: Chromatogram for standard solution
Fig. 3: Linearity plot for dolutegravir
Table 1: Results for linearity




DTG 10.0–150.0 µg/ml Y=28760x+121.8 0.999
RPV 5.0–75.0 µg/ml Y=10064x+10930 0.999
DTG: Dolutegravir, RPV: Rilpivirine





% RSD of 
assay
DTG 100 mg 100.28 0.15
RPV 50 mg 100.14 0.26
DTG: Dolutegravir, RPV: Rilpivirine, RSD: Relative standard deviation
Table 3: Results for accuracy










50 100.22 0.24 100.37 0.58
100 100.38 0.45 100.46 0.67
150 100.45 1.01 100.58 0.64
DTG: Dolutegravir, RPV: Rilpivirine, RSD: Relative standard deviation
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as flow rate (±0.2%) and organic content in mobile phase (±5%). The 
results are given in Table 4.
Stability
Stability of standard and sample solutions is studied initial to 24 h in 
stored at room temperature and 2–8°C. They are injected at different 
time intervals. The difference between initial to 24 h percentage assay 
not more than 2.0%. There is no effect in storage conditions for DTG 
and RPV drugs. The results are shown in Table 5.
Forced degradation
Forced degradation conditions such as acidic, basic, oxidative, reduction, 
thermal, hydrolysis, and photolytic stresses were attempted as per the 
International Conference of Harmonization (ICH) guidelines Q1A (R2). 
There is an effect of assay results. The results are shown in Table 6.
Recovery study for rat plasma
DTG and RPV sample were injected into rat body collected samples at 
different time intervals such as 0, 0.5, 1.0, 1.5, 2.0, and 2.5 h. After that, 
sample is prepared as per test method injected into chromatographic 
system record their values. At 2 h, the sample reaches the maximum 
result, suddenly down to 2.5 h. Results are shown in Table 7. Moreover, 
plot is shown in Fig. 5.
CONCLUSION
This method described the quantification of DTG and RPV in bulk and 
pharmaceutical formulation as per the ICH guidelines. The developed 
method was found to be accurate, precise, linear, and reliable. The 
advantage lies in the simplicity of sample preparation and the cost 
economic reagents were used. In addition, two compounds are eluted 
within 10 mins. Moreover, also, same method is used for bioanalytical 
plasma samples. The proposed HPLC conditions ensure sufficient 
resolution and the precise quantification of the compounds. Statistical 
analysis of the experimental result indicates that the precision and 
Table 4: Results for robustness
Drug 
name
Flow plus (1.2 ml/min) 
(% RSD)
Flow minus 
(0.8 ml/min) (% RSD)
Org. plus (55+45) 
(% RSD)
Org. minus (65+35) 
 (% RSD)
DTG 0.12 0.51 0.27 0.87
RPV 0.28 0.37 0.41 0.74
DTG: Dolutegravir, RPV: Rilpivirine, RSD: Relative standard deviation
Fig. 4: Linearity plot for rilpivirine
Fig. 5: Recovery plot for rat plasma





% difference RPV  
(% assay)
% difference
Initial 100.58 0.00 100.34 0.00
12 h 100.36 0.22 100.27 0.07
18 h 100.24 0.14 100.15 0.12
24 h 100.13 0.11 100.08
DTG: Dolutegravir, RPV: Rilpivirine
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reproducibility data are satisfactory. The developed chromatographic 
method can be effectively applied for routine analysis in drug research.
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Table 6: Results for forced degradation
Degradation DTG (% assay) % degradation RPV (% assay) % degradation
Control 100.45 0.00 100.38 0.00
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DTG: Dolutegravir, RPV: Rilpivirine
